We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Impedance-Based Cell Analyzer Scores in Cardiotoxicity Pilot Study

By LabMedica International staff writers
Posted on 21 Feb 2012
A cellular assay system that measures electronic impedance was used in a pilot study that examined the effect of several drug compounds on the behavior of cultures of cardiomyocytes, derived either from human induced pluripotent stem cells (hiPS), or from mouse embryonic stem cells (mESC).

Investigators at the University Medical Center (Utrecht, the Netherlands) and their collaborators at the Bioscience Department of AstraZeneca R&D (Mölndal, Sweden) worked with the Roche (Basel, Switzerland) xCELLigence Cardio instrument.

The xCELLigence Cardio instrument is powered by proprietary software and employs 96-well E-plates to measure electronic cell impedance using sensor electrodes. More...
Computer-controlled signal generation, automatic frequency scanning, and a measurement rate of 12.9 milliseconds per 96-well plate, enable high-speed precise detection of changes in cardiac cell behavior.

The aim of the current study was to test whether impedance readings could be a useful tool to detect the effects of candidate drug compounds on beating frequency (beats per minute, bpm) and arrhythmias of human induced pluripotent stem cell- and a mouse embryonic stem cell-derived cardiomyocyte line.

Results published in the December 7, 2011, issue of the journal Assay and Drug Development Technologies revealed that under the correct conditions, the beating frequency of a monolayer of cells could be recorded stably over a period of several days. Additionally, the system detected changes in beating frequency and amplitude caused by added reference compounds.

The investigators concluded that, “The xCELLigence Cardio instrument has potential for 96-well-throughput cardiotoxicity screening of the effects of compounds on rhythmic beating patterns of cardiomyocytes. There is a need for continuous improvements in the maturation of available cardiomyocytes and in further validation of the assay on an extended set of reference compounds with known in vivo effects. The production of distinct subtypes of ventricular, atrial, and nodal cardiomyocytes could open up new areas of screening for arrhythmia and cardiotoxicity.”

Related Links:

University Medical Center
AstraZeneca R&D
Roche



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.